The molecular mechanisms linking folate deficiency and neural tube defect (NTD) risk in offspring remain unclear. Folate transporters (SLC19A1, SLC46A1, SLC25A32, and FOLH1) and folate receptors (FOLR1, FOLR2, and FOLR3) are suggested to play essential roles in transporting folate from maternal intestinal lumen to the developing embryo. Loss of function variants in these genes may affect folate availability and contribute to NTD risk. This study examines whether variants within the folate transporter and receptor genes are associated with an increased risk for myelomeningocele (MM). Exons and their flanking intron sequences of 348 MM subjects were sequenced using the Sanger sequencing method and/or next generation sequencing to identify variants. Frequencies of alleles of single nucleotide polymorphisms (SNPs) in MM subjects were compared to those from ethnically matched reference populations to evaluate alleles' associated risk for MM. We identified eight novel variants in SLC19A1 and twelve novel variants in FOLR1, FOLR2, and FOLR3. Pathogenic variants include c.1265delG in SLC19A1 resulting in an early stop codon, four large insertion deletion variants in FOLR3, and a stop_gain variant in FOLR3. No new variants were identified in SLC46A1, SLC25A32, or FOLH1. In SLC19A1, c.80A>G (rs1051266) was not associated with our MM cohort; we did observe a variant allele G frequency of 61.7%, higher than previously reported in other NTD populations. In conclusion, we discovered novel loss of function variants in genes involved in folate transport in MM subjects. Our results support the growing evidence of associations between genes involved in folate transport and susceptibility to NTDs.
between folate and NTDs is unclear. No single gene has been etiologically implicated as causative of NTDs, thus association studies have targeted candidate genes in the folate metabolic pathway (Etheredge et al., 2012; Marini et al., 2011; Martinez et al., 2009; Zhang et al., 2013) .
We postulate that folate transporter and receptor genes have critical roles in supplying folate/FA from the pregnant mother through the placenta to maintain normal development of the neural tube during embryogenesis ( Figure 1 ). Folate consumed by the mother is absorbed in the small intestine, enters the maternal circulation, and is preferentially distributed to the placenta to be delivered and taken up by the developing embryo through a series of folate transporters and receptors (Solanky, Jimenez, D'Souza, Sibley, & Glazier, 2010; Yasuda et al., 2008) . Our group has previously demonstrated the association of folate transport genes with MM using a family based transmission disequilibrium test (O'Byrne et al., 2010) . The genes of interest in our study are SLC19A1 (also known as reduced folate carrier or RFC1), SLC46A1 (also known as proton-coupled folate transporter or PCFT), SLC25A32 (also known as mitochondrial folate transporter or MFTC), FOLH1 (also known as folate hydrolase), and folate receptor genes FOLR1, FOLR2, and FOLR3. Once consumed by the pregnant mother, maternal FOLH1 converts the dietary form of folate, polyglutamate-folate, into monoglutamate-folate to be transported across the apical brush-border membrane of the small intestine via folate transporters SLC46A1 and SLC19A1 (DeVos et al., 2008; O'Byrne et al., 2010; Zhao & Goldman, 2013) . Folate is stored in the liver in the form of 5-methyltetrahydrofolate (5-MTHF) and released into the maternal circulation (Zhao, Diop-Bove, Visentin, & Goldman, 2011) . Circulating 5-MTHF binds to folate receptors (e.g., FOLR1) that FIGURE 1 Folate transport pathway from mother to embryo. Folate refers to natural dietary folates and synthetic folic acid used in fortification and supplements. Folate transporters (FOLH1, SLC46A1, SLC19A1, and SLC25A32) and folate receptors (FOLR1 and FOLR2) are responsible for maternal intestinal absorption and transport of folate into cells including placental cells and the developing embryo to be utilized in metabolic pathways including the methionine cycle, homocysteine metabolic pathway, and folate mediated one-carbon metabolic pathway. Note: THF, tetrahydrofolate; FOLH, folate hydrolase; FOLR, folate receptor; SLC, human solute carrier. Modified from Petri et al. (2014) lie on the maternal side of the placenta. It has been theorized that FOLR1 and SLC46A1 are responsible for the transport of 5-MTHF via acidified endosomes during receptor-mediated endocytosis into the cytoplasm of the syncytiotrophoblast where it is then transported across the basement membrane by SLC19A1 (Solanky et al., 2010) .
Once in the fetal circulation, 5-MTHF is transported into cells via folate receptors. FOLR1 and FOLR2 are glycosylphosphatidylinositol (GPI)-anchored proteins with high affinity for folate and transport folate via endocytosis (Sabharanjak & Mayor, 2004; Solanky et al., 2010; Verma, Gullapalli, & Antony, 1992) . FOLR3, in contrast, lacks a glycosylphosphatidylinositol (GPI) signal and is a constitutively secreted form of folate receptor (Shen, Wu, Ross, Miller, & Ratnam, 1995) . Ubiquitous in cells and tissues, SLC19A1 is also responsible for transporting reduced folate into the cytoplasm, while the mitochondrial folate transporter, SLC25A32, transports cytoplasmic folate across the inner mitochondrial membrane to take part in the mitochondrial folate metabolism cycle (Titus & Moran, 2000) .
Previous genetic epidemiology studies have investigated genes of folate one-carbon metabolism and methionine cycle, but less attention has been paid to folate transport genes with the exception of SLC19A1 (Au et al., 2017 AJMG same issue) . Knockout mouse models of Slc19a1 rescued with folinic acid supplementation, a folic acid derivative, exhibit NTDs, supporting the role of SLC19A1 in NTD formation; however, human NTD populations have demonstrated variable degrees of association with the folate transporters (Gelineau-van Waes et al., 2008; Wang et al., 2012) . Only one study recently investigated SLC46A1 in cases of NTD or cleft lip and palate and failed to show an association (VanderMeer et al., 2016) . Clinical presentations of loss of function mutations of SLC46A1 have been reported in cases of hereditary folate malabsorption, consistent with nullizygous mouse models of Slc46a1 (Diop-Bove, Jain, Scaglia, & Goldman, 2013; Salojin et al., 2011; Shin, Zhao, Fiser, & Goldman, 2012; Zhao et al., 2011) . SLC25A32 nullizygous mouse embryos exhibited 100% penetrance of neural tube defects, but it is unknown if the defects were compatible with life (Kim, 2016) . In the human population, a SNP in SLC25A32 was associated with lower plasma folate levels in a Japanese population, but this gene has not been explicitly studied in human NTDs (Urano et al., 2014) . Earlier association studies involving FOLH1 and NTDs have been conflicting, but it has been suggested that maternal FOLH1 polymorphisms may increase NTD risk by influencing folate and homocysteine levels (Guo et al., 2013) . Folh1
−/− mouse model do not present with obvious birth defects but morphologically demonstrate significantly reduced axon area of the sciatic nerve suggesting a possible role in myelination of developing axons (Bacich et al., 2005) .
In regards to folate receptors, Folr1 knockout mice rescued with folate present with anterior NTDs along with cardiovascular anomalies (Zhu et al., 2007) . Human NTD cohorts have shown indirect evidence of the function folate receptors play during pregnancy with reports of low serum folic acid receptor α levels and increased levels of folate receptor autoantibodies found in mothers of NTD patients (Yang et al., 2016) . However, no association of FOLR1 or FOLR2 was discovered in earlier NTD cohorts until our group first reported an association by family based transmission-disequilibrium test by O'Byrne et al. (2010) (Barber et al., 1998; Boyles et al., 2006; Heil, van der Put, Trijbels, Gabreëls, & Blom, 1999; O'Leary et al., 2003) . In the same article, we also were the first to investigate and report association between FOLR3 and MM, but the protein function of FOLR3 in NTDs is unknown.
Thus it is our aim to examine SLC46A1, SLC19A1, SLC25A32, FOLH1, FOLR1, FOLR2, and FOLR3, for genetic variants in a large cohort of MM subjects to establish a more complete picture of the molecular mechanisms in folate deficiency and NTD risk. We hypothesize that variants within the folate transporter and receptor genes are associated with MM risk.
| MATERIALS AND METHODS
Subjects were selected from a cohort of nonsyndromic MM subjects enrolled in ongoing genetic studies in our laboratory (Au et al., 2008 (Aneji, Northrup, & Au, 2012; Tilley, Northrup, & Au, 2012) .
Additionally, another 252 MM subjects were sequenced by whole exome sequencing (WES) from the same cohort of MM affected subjects previously described (Au et al., 2008) . These subjects were born before and after 1998, up through 2008.
| DNA extraction
Genomic DNA was extracted from blood lymphocytes using the Puregene DNA extraction kid (Gentra Systems Inc., Minneapolis, MN).
Parental saliva samples were collected in some cases when blood samples were not available and the saliva DNA was prepped using the Oragene DNA preparation kid (DNA Genotek; Kanata, Ontario, Canada) following manufacturer's protocols. Working DNA was prepared as previously described (Ruggiero, Northrup, & Au, 2015 
| Sequencing
Sanger sequencing was conducted using the BigDye Terminator 3 | RESULTS 3.1 | Novel variants discovered in the study 3.1.1 | Solute carrier family
We identified a total of eight novel variants in SLC19A1 using the Sanger sequencing method and WES (Table 1) 
| Folate receptor family
Among the folate receptor genes, we discovered one novel variant in FOLR1, four novel variants in FOLR2, and nine novel variants in FOLR3 (Table 1) . Among them, five novel variants in FOLR3 involving deletion/ insertion/duplication are predicted to be damaging which we will describe here. Two variants involve deletion of exon 2 and the splice donor that involves the translation initiation codon ATG and 55 amino acids containing the signal peptide (amino acid 1-23) required for docking the ribosome to the endoplasmic reticulum (ER) and translating the protein into the ER lumen. Two other variants involve deletion of the majority of exon 5 together with the splice acceptor. We discovered several variants in FOLR2 and FOLR3 that may impact splicing and transcription, resulting in loss of protein function.
One potentially important 173bp duplication consisting of 63bp of the Sequences of the 11:71846952-53 region was analyzed using the online tool for Human Splicing Finder v2.4.1 (HSFv2.4.1). Although all MM individuals who carry one variant also carry the other variant, we evaluate all possible combinations of the two variants (gt, ct, gc, and cc) for potential effects on splicing of the FOLR3 exon 2. Compare to the reference sequence exon 2 splice acceptor (SA), the HSF results show the 11:71846952-53 gt (c.-6-41g and c.-6-40t) are at the −7 −6 position of a putative splice acceptor site (cagGC) with similar HSF matrics score (87.52 vs. 88.72) but lower MaxEnt score (7.72 vs. 5.4). Change of either c.-6-41g>c or c.-6-40t>c results in higher HSF matrics scores than the exon 2 SA. Change of c.-6-40t>c lowered the MaxEnt score to 4.7, however, the MaxEnt score for c.-6-41g>c and c.-6-41_40gt>cc increased and approaching the MaxEnt score of the FOLR3 RefSeq exon 2 SA.
Four of the 21 very rare SNPs found in SLC19A1 lead to missense changes including c.941C>T (rs200236009), and c.971C>T c.941C>T changes a polar amino acid, threonine, to a nonpolar methionine which may influence folate binding affinity of S313, an amino acid required for the binding of folate (Hou et al., 2006) .
| Common SNPs
The allele frequencies of common SNPs found in folate transporter genes are shown in Table 4 . Two-tailed Fisher's test was performed to compare allele frequencies from MM subjects and the ethnicallymatched reference populations. Two SNPs in SLC19A1 (rs150492570, rs11284347) and two SNPs in FOLR3 (rs139130389, rs1802608) were found to be associated with MM subjects with nominal significance 
| DISCUSSION
Folate is necessary for synthesis of DNA and some amino acids as well as for regulation of gene expression. During pregnancy folate demands increase by 5-to 10-fold to meet the needs of the developing fetus (Antony, 2007) . As mammals cannot produce folate de novo, the supply of folate to the developing embryo is dependent on the dietary intake of the pregnant mother in conjunction with a series of maternal and placental folate transporter proteins. Maintaining an adequate folate supply to the developing fetus relies on normal function of folate transport proteins in the mother, placenta, and embryonic cells. It is plausible that during gestation when folate demands are high, pathogenic variants in folate transporter and receptor genes in the mother and/or fetus could exacerbate a folate-deficient environment or even predispose a mother towards folate deficiency despite adequate folate intake. In our study we evaluated the genetic roles of a series of folate transporters and receptors in MM subjects.
The most studied SLC19A1 polymorphism in NTD research is A80G (rs1051266) and has been shown to be associated with MM risk in sample populations from Italy, the United States, and China, but not in the United Kingdom (De Marco et al., 2003; O'Leary et al., 2006; Pei, Liu, Zhang, Zhu, & Ren, 2009; Relton et al., 2004; Shaw et al., 2002) . A meta-analysis of these studies suggests that the A80G polymorphism is not an independent risk factor for NTD (Wang et al., 2012) . However, it is important to note that folate supplementation Pei, our study] and performed a Chi-square analysis, we found a statistically significant difference in the GG allele frequency (0.301 and 0.365, respectively; p-value 0.0468) ( Table 5) . We would expect a higher A80G occurrence rate in populations without FA fortification. Our finding corroborates the report of Slc19a1 animal models demonstrating the folate-sensitivity of the protein (Gelineau-van Waes et al., 2008) . In our cohort of 96 MM patients representing a population born during the pre-FA fortification era, the homozygous (GG) allele frequency was 37.5% among Caucasians and 41.7%
among Hispanics, among the highest when compared to the abovementioned studies. We did not show an association between A80G
and our MM cohort, however our control population of Mexican Americans derived from the 1 K Genomes Project exhibited a GG allele frequency higher than other control populations described in prior association studies involving A80G, which could point towards a genetic risk factor that may predispose U.S.-born Hispanics to myelomeningocele, an ethnic group with the highest rate of NTDs in the U.S. (Canfield et al., 2009 (Barber et al., 1998; Heil et al., 1999) . The function of FOLR3 in NTD is largely unknown, and knowledge of the biological function of FOLR3 is limited except expression has been correlated to progression of carcinomas (Corrigan et al., 2014) . However, we discovered five novel variants with deleterious consequences in the FOLR3 gene of four MM subjects strongly supporting variation in FOLR3 to be a risk factor for MM development. Consistent with our findings in an earlier study, the current study identified multiple novel loss-of-function variants in the folate receptor gene FOLR3 and noncoding variants with potential functional significance in FOLR1, FOLR2, and FOLR3 of MM subjects (O'Byrne et al., 2010) . We propose folate receptors play a bigger role in NTD development than previously recognized.
We find it significant that no variants have been discovered in coding regions of FOLH1, SLC46A1, and SLC25A32 in MM subjects. As neural tube closure occurs prior to embryonic gut development, FOLH1 and SLC46A1 expression may not be involved in neural tube development. Further investigation is warranted examining these genes in the mothers of MM subjects as impaired protein enzyme activity could inhibit intestinal absorption during pregnancy further impacting in-utero neural tube development.
| Strengths and limitations
There are several strengths of our study. Our study cohort includes the two ethnicities (Mexican American and Caucasian) that have the highest rates of NTDs in North America. In addition, we were able to study a large sample population totaling 348 MM cases. Lastly, we used parental DNA of the MM subjects to determine heritability patterns of novel variants.
Some limitations of our study include a lack of data on maternal dietary intake of folate or folate levels. Also, our study used a retrospective design. Moreover, we had a small sample size of subjects for whom we utilized Sanger sequencing and a low minor allele frequency of SNPs thus restricting the power of the study to identify significant associations between SNPs with low rare allele frequency and our study cohort affected with MM. Therefore, due to our overall sample size, caution should be used when comparing the rare allele frequency in our subject population with reported population frequencies. This study is limited to examining the genetic variants effects on folate transportation in relation to the placental and fetal tissues because we only tested affected subjects with full sequencing.
Presence of un-transmitted genetic variants in the pregnant mother
were not detected as parental samples were only studied to determine status (inherited vs. de novo) of variants found in affected subjects. In In addition, we need to pursue additional studies assessing the potential impact these newly discovered variants have on the physiologic function of genes in the folate metabolism pathway.
Comparing these findings to unaffected controls will further help to improve our understanding of the contribution that both genetic and environmental factors have in the development of NTDs.
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